Search clinical trials for: CDC-0449 oral suspension (labeled)

Total 355 results

Genentech, Inc.

Completed

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Healthy
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

Adult Medulloblastoma

United States
Genentech, Inc.

Approved for marketing

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

Basal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Recurrent Childhood Medulloblastoma

United States
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Recurrent Childhood Medulloblastoma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
NYU College of Dentistry
Genentech, Inc.

Completed

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors (KCOT)

Keratocystic Odontogenic Tumor

United States
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Chronic Lymphocytic Leukemia | Primary Central Nervous System Lymphoma | Diffuse Large B-cell Lymphoma | Indolent Non-hodgkin Lymphoma

France
Genentech, Inc.
National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center...

Completed

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
UCSF Benioff Children's Hospital Oakland
Genentech, Inc.

Completed

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) (GDC-0449)

Basal Cell Nevus Syndrome | Gorlin Syndrome

United States
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Ovarian Cancer
Anne Chang
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

Skin Basal Cell Carcinoma

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1205

Healthy

Belgium
reMYND

Recruiting

A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

Alzheimer Disease

Netherlands, Spain
National Cancer Institute (NCI)

Completed

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Recurrent Uterine Corpus Sarcoma | Chondrosarcoma | Recurrent Osteosarcoma | Gastrointestinal Stromal Tumor | Clear Cell Sarcoma of the Kidney | Metastatic Osteosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult... and other conditions

United States
Glock Health, Science and Research GmbH

Completed

G-PUR® for Reduced Lead Bioavailability

Lead Exposure

Austria
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Diabetes Mellitus, Type 2

United Kingdom
Tesaro, Inc.

Completed

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Cancer

Netherlands
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
Vanda Pharmaceuticals

Completed

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Healthy

United States
Rebiotix Inc.

Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Clostridium Difficile Infection (CDI)

United States, Canada
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
Vifor Fresenius Medical Care Renal Pharma
Tigermed Consulting Co., Ltd

Recruiting

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (Patiromer JADE)

Renal Insufficiency, Chronic | Hyperkalemia

China
Vanda Pharmaceuticals

Recruiting

Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances

Sleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological Disorder

United States
Galapagos NV

Terminated

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Healthy

Netherlands
Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Healthy

Belgium
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Healthy

Canada
ReveraGen BioPharma, Inc.

Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis
Relypsa, Inc.

Terminated

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Hyperkalemia

United States
Relypsa, Inc.

Completed

Patiromer With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Hyperkalemia

United States
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Type 2 Diabetes Mellitus
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Relypsa, Inc.

Completed

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) (OPAL)

Chronic Kidney Disease (CKD) | Hyperkalemia (HK)

United States, Croatia, Czechia, Denmark, Georgia, Hungary, Italy, Serbia, Slovenia, Ukraine
Noxopharm Limited

Withdrawn

A Study of Safety and Tolerability of NOX66 in Healthy Volunteers

Healthy Volunteers

Australia
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Healthy

Belgium
Steno Diabetes Center Copenhagen
Zealand University Hospital; AstraZeneca

Unknown

The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia (ZIRCUS)

Type 2 Diabetes Mellitus With Kidney Complications

Denmark
Pfizer

Completed

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

Healthy Male Subjects

Netherlands
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Genentech, Inc.

Completed

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers

United States
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom

3

Subscribe